Vodobatinib (Cat No.:I038095) is a selective, orally available tyrosine kinase inhibitor (TKI) targeting BCR-ABL1, including resistant mutations like T315I, commonly found in chronic myeloid leukemia (CML). It inhibits kinase activity while sparing many off-target kinases, potentially reducing adverse effects compared to earlier-generation TKIs. Vodobatinib has shown strong preclinical and early clinical efficacy in patients with CML who are intolerant or resistant to other TKIs. Its favorable pharmacokinetic profile and mutation coverage position it as a promising candidate for overcoming treatment resistance in hematologic malignancies.